Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

Circulation. 2004 Jun 1;109(21):2492-9. doi: 10.1161/01.CIR.0000131449.94713.AD.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Angiotensin II / antagonists & inhibitors
  • Angiotensin II / biosynthesis
  • Angiotensin II Type 1 Receptor Blockers*
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Animals
  • Cardiovascular Agents / administration & dosage
  • Cardiovascular Agents / therapeutic use
  • Diabetic Nephropathies / prevention & control
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Humans
  • Hypertension / drug therapy*
  • Kidney Diseases / prevention & control
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Proteinuria / drug therapy
  • Rats
  • Renin-Angiotensin System / drug effects*
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / etiology

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Cardiovascular Agents
  • Angiotensin II